Our data confirmed the sensitizing effect of a CDK4/6 inhibitor on lapatinib and suggested mechanisms by which lapatinib and palbociclib synergistically work against HER2 therapy-resistant breast cancer in a nude mouse model. This evidence concerns the gene ERBB2 and breast carcinoma.